Ankyra Therapeutics
PrivateLast Round
Series B
Nov 12, 2021
Total Funding Raised
$50M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Ankyra Therapeutics is a biotechnology company that develops anchored-drug conjugates to enhance the safety and effectiveness of cytokine immunotherapies for cancer patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ankyra Therapeutics Comparables
Compare Ankyra Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Xilio Therapeutics | 83% | |
| Bright Peak Therapeutics | 79% | |
| Synthekine | 79% |
For institutional investors. Book with your work email.
Ankyra Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 12, 2021 | ||||
| Series A | May 4, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ankyra Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GV | Series B |
| Fidelity Management & Research Company | Series B |
| Borealis Ventures | Series B |
| Polaris Partners | Series B, Series A |
| Sands Capital | Series B |
| Spring Mountain Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 41% MoM.
- Apr 16, 2026
Clinical presentations on novel IL-12 immunotherapy at AACR 2026.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 21, 2026
On Sep 21st '26, Ankyra Therapeutics, Inc. is developing ANK-101 with Johnson & Johnson, and local administration allows higher drug concentrations with fewer safety issues.
For institutional investors. Book with your work email.
Ankyra Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ankyra Therapeutics's valuation, stock price, and market status.
Is Ankyra Therapeutics a public or private company?
Ankyra Therapeutics is a private company.
What is the current stock price of Ankyra Therapeutics?
Ankyra Therapeutics is a private company, so its shares have no public market price. Caplight tracks Ankyra Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ankyra Therapeutics worth (valuation)?
Valuation information for Ankyra Therapeutics is not publicly available.
Can I buy Ankyra Therapeutics stock?
Ankyra Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ankyra Therapeutics's last funding round?
Ankyra Therapeutics's most recent funding round was Series B on November 12, 2021.
Who are the main investors in Ankyra Therapeutics?
Key investors in Ankyra Therapeutics include Polaris Partners, Sands Capital, Spring Mountain Capital.
Will Ankyra Therapeutics IPO soon?
No public IPO plans have been announced for Ankyra Therapeutics.
How can I track Ankyra Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Ankyra Therapeutics's shares on secondary markets.